Did You Know...
...that the first rickshaw was invented in 1869 by an American Baptist minister, the Rev. E. Jonathan Scobie, to transport his invalid wife around the streets of Yokohama?
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8148498 | DKK-1 antibodies The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1. ... | 04/03/2012 |
| 8076298 | Treating acute renal failure with soluble thrombomodulin variants The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction wit... | 12/13/2011 |
| 7989585 | Chronic treatment regimen using glucagon-like insulinotropic peptides The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range. ... | 08/02/2011 |
| 7988970 | Methods of treatment comprising administering an anti-sclerostin antibody Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bon... | 08/02/2011 |
| 7582608 | Selective VPAC2 receptor peptide agonists The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. ... | 09/01/2009 |
| 7482321 | Extended glucagon-like peptide-1 analogs The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability. ... | 01/27/2009 |
| 7435799 | TNF-α binding molecules The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation... | 10/14/2008 |
| 7262277 | Antagonistic anti-hFAS ligand human antibodies and fragments thereof Human antibodies, preferably recombinant human antibodies that specifically bind to human Fas Ligand (hFasL) are disclosed. These antibodies have high affinity for hFasL, a slow off rate for hFasL dissociation and neutralize a Fas Ligand activity in vitro and in viv... | 08/28/2007 |
| 7259233 | Chronic treatment regimen using glucagon-like insulinotropic peptides The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range. ... | 08/21/2007 |
| 7238663 | Pre-mixes of GLP-1 and basal insulin The present invention encompasses pre-mixed formulations comprising a GLP-1 polypeptide and a basal insulin. ... | 07/03/2007 |
| 7179788 | Biphasic mixtures of GLP-1 and insulin The present invention encompasses pharmaceutical formulations comprising a biphasic mixture which comprises a glucagon like peptide (GLP-1) compound in a solid phase and an insulin in a solution phase. ... | 02/20/2007 |
| 7175996 | Methods of optimizing antibody variable region binding affinity The present invention relates to compositions and methods of producing higher affinity molecules, and in particular, higher affinity antibodies. Specifically, the invention contemplates methods of mutagenesis to create a population of oligonucleotides coding for alt... | 02/13/2007 |
| 7144863 | GLP-1 formulations with protracted time action The present invention encompasses compositions wherein a GLP-1 compound is complexed with a basic polypeptide. The compositions provide a prolonged duration of action and can be administered by the pulmonary route. ... | 12/05/2006 |
| 7101978 | TNF-α binding molecules The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation... | 09/05/2006 |
